Abstract
Major depressive disorder (MDD) has been a prominent topic in recent years due to its unknown etiology and pathology, high prevalence rate, and the high cost of treatment. Due to its high resolution for soft tissue, magnetic resonance imaging (MRI) has become an essential noninvasive tool for the evaluation of the brain substrates underlying mental disorders. MRI enables characterization of brain morphology and function in MDD patients. Compared to healthy controls, MDD patients have structural changes in certain brain regions such as the prefrontal cortex, cingulate cortex, precuneus, thalamus, and hippocampus. Abnormal brain functions as indicated by various MRI measurements including region homogeneity, the amplitude of low-frequency fluctuation, functional connectivity, and mean kurtosis may also contribute to the pathogenesis of MDD. This mini-review summarizes recent MRI findings on the neural manifestations of MDD. We discuss the potential of MRI biomarkers that may prove clinically useful for early diagnosis and evaluation of treatment outcomes for depression.
Keywords: Major depressive disorder, magnetic resonance imaging, brain morphology, brain function, mini-review, pathology.
Current Pharmaceutical Design
Title:Major Depressive Disorder and Magnetic Resonance Imaging: A Mini-Review of Recent Progress
Volume: 24 Issue: 22
Author(s): Hui Qiu and Junfeng Li*
Affiliation:
- Department of Radiology, Heping Hospital of Changzhi Medical College, Shanxi, 046000,China
Keywords: Major depressive disorder, magnetic resonance imaging, brain morphology, brain function, mini-review, pathology.
Abstract: Major depressive disorder (MDD) has been a prominent topic in recent years due to its unknown etiology and pathology, high prevalence rate, and the high cost of treatment. Due to its high resolution for soft tissue, magnetic resonance imaging (MRI) has become an essential noninvasive tool for the evaluation of the brain substrates underlying mental disorders. MRI enables characterization of brain morphology and function in MDD patients. Compared to healthy controls, MDD patients have structural changes in certain brain regions such as the prefrontal cortex, cingulate cortex, precuneus, thalamus, and hippocampus. Abnormal brain functions as indicated by various MRI measurements including region homogeneity, the amplitude of low-frequency fluctuation, functional connectivity, and mean kurtosis may also contribute to the pathogenesis of MDD. This mini-review summarizes recent MRI findings on the neural manifestations of MDD. We discuss the potential of MRI biomarkers that may prove clinically useful for early diagnosis and evaluation of treatment outcomes for depression.
Export Options
About this article
Cite this article as:
Qiu Hui and Li Junfeng *, Major Depressive Disorder and Magnetic Resonance Imaging: A Mini-Review of Recent Progress, Current Pharmaceutical Design 2018; 24 (22) . https://dx.doi.org/10.2174/1381612824666180727111651
DOI https://dx.doi.org/10.2174/1381612824666180727111651 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Environmental Enrichment as a Positive Behavioral Intervention Across the Lifespan
Current Neuropharmacology Systems Biology in Aging: Linking the Old and the Young
Current Genomics Brain Innate Immunity in the Regulation of Neuroinflammation: Therapeutic Strategies by Modulating CD200-CD200R Interaction Involve the Cannabinoid System
Current Pharmaceutical Design Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design Molecular Classification and Drug Response Prediction in Cancer
Current Drug Targets Evaluation of 170 Xenobiotics as Transactivators of Human Pregnane X Receptor (hPXR) and Correlation to Known CYP3A4 Drug Interactions
Current Drug Metabolism Combination of Therapeutic Hypothermia and Other Neuroprotective Strategies after An Ischemic Cerebral Insult
Current Neuropharmacology Amniotic Fluid Embolism: Moving Diagnosis Through the Time. From the Mechanical Pulmonary Vascular Occlusion Until An Immuno - Inflammatory Pathogenesis?
Current Pharmaceutical Biotechnology The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets Reliability of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) in longitudinal Studies
Current Alzheimer Research Mitochondrial Targeting for Development of Novel Drug Strategies in Brain Injury
Central Nervous System Agents in Medicinal Chemistry Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews The Expression of Relaxin-3 in Adipose Tissue and its Effects on Adipogenesis
Protein & Peptide Letters Nicotine-Derived Compounds as Therapeutic Tools Against Post-Traumatic Stress Disorder
Current Pharmaceutical Design Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment
Current Neuropharmacology Delivery and Application of Dietary Polyphenols to Target Organs, Tissues and Intracellular Organelles
Current Drug Metabolism Endocrine Disruptors and Human Health
Mini-Reviews in Medicinal Chemistry Cognitive Mechanisms in Decision-Making in Patients With Mild Alzheimer Disease
Current Alzheimer Research Biological Effects of Curcumin and Its Role in Cancer Chemoprevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry